Merck Animal Health Invests $895 Million to Expand U.S. Vaccine Production and R&D

29/05/2025

Merck Animal Health, a division of Merck & Co., Inc., has announced an $895 million investment to expand its manufacturing and R&D facilities in De Soto, Kansas, according to the company’s official press release.

The initiative includes $860 million for upgrading production capacity for large-molecule biologics and vaccines, and an additional $35 million to expand research and development labs. This is the largest single investment Merck Animal Health has ever made and ranks as the second-largest private investment in Kansas history.

Strategic and Economic Significance

The expansion is expected to create over 200 new jobs, signaling a strong commitment to both innovation and economic development in the U.S. Midwest. Strategically located within the Animal Health Corridor — a region known for its concentration of animal health companies and institutions — De Soto provides a well-developed ecosystem for biologic manufacturing.

Business Drivers Behind the Investment

Merck’s decision aligns with several macroeconomic and sector-specific factors:

•    A global increase in demand for veterinary vaccines, driven by concerns about zoonotic diseases and livestock productivity

•    Growing consumer awareness of food safety and traceability, leading to a preference for vaccinated, antibiotic-free meat

•    Rising technological barriers to entry in biologics, making infrastructure a competitive differentiator

Long-Term Market Positioning

This investment bolsters Merck Animal Health’s long-term capacity to serve both livestock and companion animal markets. It also reflects a strategic shift toward biologic innovation, as companies in the sector seek to move away from traditional chemical treatments toward targeted, immune-based therapies.

The scale of the investment highlights the sector’s capital intensity and the importance of vertical integration — from R&D to full-scale manufacturing — to meet global regulatory and logistical challenges.